Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 115-121

  Barbara, Giovanni ^a   Stanghellini, Vincenzo ^a   Cremon, Cesare ^a   De Giorgio, Roberto ^a   Fronzoni, Lucia ^a   Serra, Mauro ^a   Corinaldesi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Abdominal pain; Aminosalicylates; Immune activation; Irritable bowel syndrome; Mast cells

Indexed keywords

CETIRIZINE; CHEMOKINE; CROMOGLYCATE DISODIUM; CYTOKINE; ENDORPHIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; KETOTIFEN; MESALAZINE; MESSENGER RNA; PREDNISOLONE; PROTEINASE; RANITIDINE; TRYPSIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ALLODYNIA; BLOATING; CAMPYLOBACTER; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLON; CONFERENCE PAPER; CROHN DISEASE; DEPRESSION; DESCENDING COLON; DIARRHEA; DUODENUM; FATIGUE; GASTROENTERITIS; GENE EXPRESSION; HUMAN; HYPERALGESIA; ILEUM; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INTESTINE CELL; INTESTINE FUNCTION; IRRITABLE COLON; LYMPHOCYTE COUNT; MAST CELL; MICROSCOPIC COLITIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECTUM; REMISSION; STEROID THERAPY; T LYMPHOCYTE; ULCERATIVE COLITIS; VISCERA;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MAST CELLS; STEROIDS;

EID: 77950825420     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268131     Document Type: Conference Paper

References (63)

1. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G: Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-252.
2. Santos J, Alonso C, Guilarte M, Vicario M, Malagelada JR: Targeting mast cells in the treatment of functional gastrointestinal disorders. Curr Opin Pharmacol 2006; 6: 541-546.
3. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Corinaldesi R: What is the effect of inflammation on intestinal function? Inflamm Bowel Dis 2008; 14:S140-S144.
4. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R: New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20(suppl 2):1-9. (Pubitemid 39237523)
5. Isgar B, Harman M, Kaye MD, Whorwell PJ: Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-192.
6. Limsui D, Pardi DS, Camilleri M, Loftus EV Jr, Kammer PP, Tremaine WJ, Sandborn WJ: Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007; 13: 175-181.
7. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-396.
8. Spiller R, Garsed K: Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988.
9. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
10. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N: Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-1347
11. Aerssens J, Camilleri M, Talloen W, Thielemans L, Göhlmann HW, Van Den Wyngaert I, Thielemans T, De Hoogt R, Andrews CN, Bharucha AE, Carlson PJ, Busciglio I, Burton DD, Smyrk T, Urrutia R, Coulie B: Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205.
12. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551.
13. Park MI, Camilleri M: Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006; 18: 595-607.
14. Taché Y, Bonaz B: Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007; 117: 33-40.
15. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R: Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol 2008; 42(suppl 3):S214-S217.
16. Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, Sweetser S, Singh R: Measurement of serum 7alpha-hydroxy- 4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009; 21: 734-743.
17. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M: Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
18. Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-1583.
19. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783.
20. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR: Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209.
21. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-1595.
22. Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Ag reus L: Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-773.
23. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G: Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
24. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457.
25. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S: Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-929.
26. Piche T, Saint-Paul MC, Dainese R, Marine- Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hébuterne X: Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473.
27. Klooker TK, Koopman KE, Heide S, Wijngaard RM, Boeckxstaens GE: Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Neurogastroenterol Motil 2008; 20(suppl 1): A16.
28. Macsharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM: Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-1476.
29. Barbara G, Wang B, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R: Mast celldependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
30. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M: Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-1434.
31. Róka R, Rosztóczy A, Leveque M, Izbéki F, Nagy F, Molnár T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L: A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 550-555.
32. Ossovskaya VS, Bunnett NW: Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
33. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC: Abnormal intestinal permeability in subgroups of diarrhea- predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294.
34. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM, Walkerton Health Study Investigators: Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-450.
35. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, Spiller RC: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77-84.
36. Kavelaars A, Ballieux RE, Heijnen CJ: Betaendorphin secretion by human peripheral blood mononuclear cells: regulation by glucocorticoids. Life Sci 1990; 46: 1233-1240.
37. Stein C, Hassan AH, Przewłocki R, Gramsch C, Peter K, Herz A: Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 1990; 87: 5935-5939.
38. Verma-Gandhu M, Bercik P, Motomura Y, Verdu EF, Khan WI, Blennerhassett PA, Wang L, El-Sharkawy RT, Collins SM: CD4+ T-cell modulation of visceral nociception in mice. Gastroenterology 2006; 130: 1721-1728.
39. Bolin TD: Use of oral sodium cromoglycate in persistent diarrhoea. Gut 1980; 21: 848-850.
40. Lunardi C, Bambara LM, Biasi D, Cortina P, Peroli P, Nicolis F, Favari F, Pacor ML: Double- blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991; 21: 569-572.
41. Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, Di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G, Manghisi O, Marsigli L, Mazzacca G, Rigo L, Sacerdoti G, Scolozzi R, Surreni C, Grazioli I, Melzi G: Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type: multicenter study of 428 patients. Scand J Gastroenterol 1995; 30: 535-541.
42. Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G: Oral disodium cromoglycate treatment of irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992; 87: 55-57.
43. Paganelli R, Fagiolo U, Cancian M, Sturniolo GC, Scala E, D'Offizi GP: Intestinal permeability in irritable bowel syndrome. Effect of diet and sodium cromoglycate administration. Ann Allergy 1990; 64: 377-380.
44. Martinez C, Ramos L, Mosquera JL, Alonso C, Guilarte M, Vicario M, de Torres I, Casellas F, Saperas E, Santos J, Malagelada JR: Relevant transcriptional changes after longterm mast cell stabilization in the jejunal mucosa of diarrhea-prone irritable bowel syndrome. Gastroenterology 2008; 4(suppl 1):A28.
45. Travis SPL, Stange EF, Lémann M, et al, European Crohn's and Colitis Organisation (ECCO): European consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
46. Brogden RN, Sorkin EM: Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38: 500-523.
47. Greenfield SM, Punchard NA, Teare JP, Thompson RP: The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-383.
48. Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM: Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27: 479-485.
49. Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R: Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-414.
50. Fox CC, Moore WC, Lichtenstein LM: Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5- aminosalicylic acid. Dig Dis Sci 1991; 36: 179-184.
51. Bissonnette EY, Enciso JA, Befus AD: Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol 1996; 156: 218-223.
52. Bafutto M, Almeida JR, Leite NV, Filho JR: Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii . Gastroenterology 2008; 4(suppl 1):A527.
53. Bafutto M, Almeida JR, Almeida RC, Almeida TC, Leite NV, Filho JR: Treatment of postinfectious irritable bowel syndrome and non infective irritable bowel syndrome with mesalazine. Gastroenterology 2008; 4(suppl 1): A672.
54. Andrews CN, Petcu R, Griffiths T, Bjarnason J, Chapman K, Cellars L, Vergnolle N, Rioux KP: Mesalamine alters colonic mucosal proteolytic activity and fecal bacterial profiles in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2008; 4(suppl 1):A548.
55. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201: 1205-1215.
56. Di Paolo MC, Merrett MN, Crotty B, Jewell DP: 5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Gut 1996; 38: 115-119.
57. Macdonald TT, Monteleone G: Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-1925.
58. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M: Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625-633.
59. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM: High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615.
60. Matter SE, Bhatia PS, Miner PB Jr: Evaluation of antral mast cells in nonulcer dyspepsia. Dig Dis Sci 1990; 35: 1358-1363.
61. Su X, Gebhart GF: Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76: 105-114. (Pubitemid 28304946)
62. Clouse RE, Lustman PJ, Geisman RA, Alpers DH: Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416.
63. Jakate S, Demeo M, John R, Tobin M, Keshavarzian A: Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med 2006; 130: 362-367.